Showing 1361-1370 of 9336 results for "".
- Study: Transgender Individuals Experience Stigma, Treatment Barriershttps://practicaldermatology.com/news/lived-experience-of-acne-and-acne-treatment-in-transgender-patients/2462206/New research sheds light on the lived experiences of transgender individuals who have acne. "While acne is common in transgender and gender-diverse people and is associated with gender-affirming hormone therapy, little research has examined these factors and their impact in gender minority groups…
- FDA Deems Vaporized Hydrogen Peroxide an Established Method of Sterilizationhttps://practicaldermatology.com/news/fda-deems-vaporized-hydrogen-peroxide-an-established-method-of-sterilization/2462205/The U.S. Food and Drug Administration (FDA) announced that it now considers vaporized hydrogen peroxide (VHP) as an established method of sterilization for medical devices. In what the agency called a recognition of its long-time effectiveness, it revised the final guidance on the Submission and R…
- Novartis Set to Acquire Calypso Biotech, Focused on IL-15 Targeted Therapieshttps://practicaldermatology.com/news/novartis-set-to-acquire-calypso-biotech-focused-on-il-15-targeted-therapies/2462204/European-based biotech manufacturer Calypso has entered into an agreement to be acquired by Novartis, according to a press release. "We are excited for this transaction with Novartis," Calypso CEO and Founder Alain Vicari said in a news release. "As part of the Novartis portfolio, CALY-002 is in …
- Interim Analysis Shows Dupilumab Safe, Effective for AD Treatment at 2 Yearshttps://practicaldermatology.com/news/real-world-effectiveness-of-dupilumab-in-adult-and-adolescent-patients-with-atopic-dermatitis-2-year-interim-data-from-the-prose-registry/2462202/Dupilumab was associated with improved disease control in patients with moderate-to-severe atopic dermatitis (AD) at two years, according to a new interim analysis. The study, published in Dermatology and Therapy, examined two-year data from the PROSE AD Registry (an ongoing, prospective, observat…
- Co-occurring Autistic Spectrum Disorder Mediates ADHD on Atopic Dermatitis, Acnehttps://practicaldermatology.com/news/co-occurring-asd-mediates-impact-of-adhd-on-atopic-dermatitis-and-acne-a-retrospective-cohort-study/2462200/Both male and females who were diagnosed with attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) showed different risks for acne and eczema, according to a study. "Our study is the first to examine the association between ASD, ADHD, and two of the most common skin d…
- Topical Steroids and Bone Healthhttps://practicaldermatology.com/news/topical-steroids-and-bone-health/2462197/Recently released study data found that higher doses of topical corticosteroids, such as those often used to treat inflammatory skin disorders, are tied to increased risks for osteoporosis and bone fractures associated with osteoporosis. Based on data from the Taiwan National Health Insurance Resea…
- Triple Combo Acne Gel Well-tolerated in Two Studieshttps://practicaldermatology.com/news/triple-combo-acne-gel-well-tolerated-in-phase-2-study/2462194/A triple combination acne gel (IDP-126) was shown to be safe and effective in two phase 3 studies, according to a new analysis. Researchers publishing in the Journal of the American Academy of Dermatology analyzed the results of two phase 3, double-blind, 12-week studies that randomized participan…
- Lower Extremity Lymphedema Linked with Increased Risk for Skin Cancerhttps://practicaldermatology.com/news/lower-extremity-lymphedema-linked-with-increased-risk-for-skin-cancer/2462193/New research suggests that patients with lower extremity lymphedema are at an increased risk for skin cancer. Researchers writing in Mayo Clinic Proceedings enrolled more than 4,400 patients with lower extremity lymphedema in the study, and constructed Kaplan-Meier curves for the cohorts to exami…
- Vidac Queues Up Phase 2b Study for Potential Actinic Keratosis Therapyhttps://practicaldermatology.com/news/vidac-pharma-to-conduct-phase-2b-study-for-actinic-keratosis-therapeutic-candidate-vda-1102-with-centroderm/2462192/Vidac Pharma Holdings recently announced the commencement of a Phase 2b trial for its candidate therapy (VDA-1102) to treat actinic keratosis (AK), and has engaged with a research team from a leading clinical dermatology clinical research institute (CentroDerm GmbH). According to the manufacturer,…
- Seaweed- and Carbonated Water-based Hydrogel Shows Promise for Treatment of Skin Woundshttps://practicaldermatology.com/news/revolutionary-seaweed-and-carbonated-water-based-hydrogel-for-treating-skin-wounds/2462184/Results from a new study suggested promise for a new seaweed- and carbonated water-based hydrogel that aims to prevent the temporary dilation of wound sites. Researchers developed a low-adhesion, low-swelling hydrogel using alginate, which is non-adhesive to cells and to skin tissue, as well as Ca…